SAN DIEGO, Dec. 7, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate as a silver level sponsor and feature its new C360™ cervical spine portfolio at the Cervical Spine Research Society (CSRS) 48th Annual Meeting held virtually from December 9-12, 2020.
"The recent launch of our anterior cervical plating system and our sponsorship of the CSRS Annual Meeting underscore our investment in and commitment to providing innovative technology to address cervical spine diseases," said Massimo Calafiore, executive vice president, Global Business Units at NuVasive. "We look forward to showcasing our procedurally integrated cervical spine portfolio that reflects our mission to transform surgery, advance care and change lives."
NuVasive will host a virtual exhibit featuring its new Anterior Cervical Plating (ACP) system that challenges the status quo of cervical spine technology, and consists of:
- Three plate profiles, including the thinnest plate on the market1 for one and two levels, with optimized plate stiffness to support construct stability;
- A wide array of implant length options to match a variety of patient anatomies and to facilitate maximizing the distance from the adjacent levels; and
- A range of advanced screw offerings with integrated locking covers to facilitate optimized screw placement and locking.
The procedurally integrated C360 cervical spine portfolio also includes Reline® Cervical, a posterior fixation system expected to be commercially available in 2021,2 and integrates with best-in-class access instrumentation, implants, enabling technologies and biologic materials into a procedural solution.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes access, implants and fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in net sales, NuVasive has approximately 2,800 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
1Data on file. Based on review of publicly available materials at the time of this release.
2Reline Cervical is not yet commercially available. The timeline for availability cannot be guaranteed.
The NuVasive ACP system incorporates technology developed by Gary K. Michelson, M.D.
View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvasive-to-feature-its-c360-portfolio-at-the-cervical-spine-research-society-48th-annual-meeting-301187139.html
SOURCE NuVasive, Inc.
Investor Contact - Suzanne Hatcher, NuVasive, Inc., 858-458-2240, firstname.lastname@example.org; Media Contact - Jessica Tieszen, NuVasive, Inc., 858-736-0364, email@example.com